normative

Hard-to-Value Firms Include Biotech and Discrete-Risk Names

Companies like Moderna are too hard to value intrinsically because the value depends on specialized medical knowledge, and firms where ownership protection is uncertain, such as Russian or Chinese companies, are also too hard, so he avoids Chinese equities.

normativepending

Speaker

Aswath

Evidence Quote

“The more uncertain you feel about legal protection of your ownership rights, the less willing you should be to value a company”

Source

Aswath Damodaran - Making Sense of the Market Pt. 2 - [Invest Like the Best, EP.349]— Invest Like the Best
Created: 11/14/2026, 2:17:06 AM

Your notes

Loading notes...